CO5580744A2 - Forma de dosificacion oral de un profarmaco de sulfonamida - Google Patents
Forma de dosificacion oral de un profarmaco de sulfonamidaInfo
- Publication number
- CO5580744A2 CO5580744A2 CO04042439A CO04042439A CO5580744A2 CO 5580744 A2 CO5580744 A2 CO 5580744A2 CO 04042439 A CO04042439 A CO 04042439A CO 04042439 A CO04042439 A CO 04042439A CO 5580744 A2 CO5580744 A2 CO 5580744A2
- Authority
- CO
- Colombia
- Prior art keywords
- composition
- drug
- compound
- nhr1
- parecoxib
- Prior art date
Links
- 239000006186 oral dosage form Substances 0.000 title 1
- 229940124530 sulfonamide Drugs 0.000 title 1
- 150000003456 sulfonamides Chemical class 0.000 title 1
- 229940079593 drug Drugs 0.000 abstract 6
- 239000003814 drug Substances 0.000 abstract 6
- 239000000203 mixture Substances 0.000 abstract 6
- 150000003839 salts Chemical class 0.000 abstract 6
- 150000001875 compounds Chemical class 0.000 abstract 5
- 229960004662 parecoxib Drugs 0.000 abstract 4
- TZRHLKRLEZJVIJ-UHFFFAOYSA-N parecoxib Chemical compound C1=CC(S(=O)(=O)NC(=O)CC)=CC=C1C1=C(C)ON=C1C1=CC=CC=C1 TZRHLKRLEZJVIJ-UHFFFAOYSA-N 0.000 abstract 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 3
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000004702 alkoxy alkyl carbonyl group Chemical group 0.000 abstract 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000004703 alkyl carbonyl aminoalkyl carbonyl group Chemical group 0.000 abstract 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000004181 carboxyalkyl group Chemical group 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 229960000590 celecoxib Drugs 0.000 abstract 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- WAZQAZKAZLXFMK-UHFFFAOYSA-N deracoxib Chemical compound C1=C(F)C(OC)=CC=C1C1=CC(C(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 WAZQAZKAZLXFMK-UHFFFAOYSA-N 0.000 abstract 1
- 229960003314 deracoxib Drugs 0.000 abstract 1
- 125000005223 heteroarylcarbonyl group Chemical group 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 125000005182 hydroxyalkylcarbonyl group Chemical group 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- -1 phenylcarbonyl phenyl (hydroxy) methylcarbonyl Chemical group 0.000 abstract 1
- 229960002004 valdecoxib Drugs 0.000 abstract 1
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
1.- Una composición farmacéutica sustancialmente anhidra y que comprende al menos una unidad de dosificación que comprende una cantidad terapéuticamente efectiva de un compuesto X-SO2-NHR1, o una sal farmacéuticamente aceptable de éste, en el que X es un resto seleccionado de manera que el compuesto X-SO2-NH2 es un fármaco conocido, siendo el compuesto X-SO2-NHR1 o una sal de éste fácilmente degradables ex vivo al fármaco X-SO2-NH2; y en el que R1 es un grupo, que no tiene más de 8 átomos de carbono, seleccionado de entre los grupos alquilo, hidroxialquilo, alcoxialquilo, carboxialquilo, acilo, alquilcarbonilo, alcoxicarbonilo, hidroxialquilcarbonilo, alcoxialquilcarbonilo, carboxialquilcarbonilo, aminoalquilcarbonilo, fenilcarbonilo, bencilcarbonilo, fenil(hidroxi)metilcarbonilo, alcoxicarbonilcarbonilo, alcoxicarbonilalquilcarbonilo, alcoxicarbonilalquilcarbonilo, alquilcarbonilaminoalquilcarbonilo, alcoxicarbonilaminoalquilcarbonilo, alcoxicarbonilcarbonilo, resto de aminoácido y grupos heteroarilcarbonilo; siendo dicha composición administrable por vía oral y con medios para inhibir la degradación del compuesto X-SO2-NHR1 o una sal de éste al fármaco X-SO2-NH2 previa a la administración oral.2.- La composición de la reivindicación 1 en la que el fármaco X-SO2-NH2 es un fármaco inhibidor selectivo de la COX-2.3.- La composición de la reivindicación 1 en la que el fármaco X-SO2-NH2 se selecciona de entre el grupo que comprende valdecoxib, celecoxib y deracoxib.4.- La composición de la reivindicación 1 en la que el compuesto X-SO2- NHR1 es parecoxib y se presenta en forma del ácido libre de parecoxib o como una sal farmacéuticamente aceptable de éste soluble en agua.5.- La composición de la reivindicación 4 en la que la cantidad de parecoxib o de una sal soluble en agua de éste en cada unidad de dosificación es de aproximadamente 1 mg a aproximadamente 200 mg.6.- La composición de la reivindicación 4 en la que la cantidad de parecoxib o de una sal soluble en agua de éste en cada unidad de dosificación es de aproximadamente 5 mg a aproximadamente 120 mg.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35059601P | 2001-11-13 | 2001-11-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5580744A2 true CO5580744A2 (es) | 2005-11-30 |
Family
ID=23377399
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO04042439A CO5580744A2 (es) | 2001-11-13 | 2004-05-07 | Forma de dosificacion oral de un profarmaco de sulfonamida |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20030100595A1 (es) |
| EP (1) | EP1446118B1 (es) |
| JP (1) | JP2005509002A (es) |
| KR (1) | KR20050044459A (es) |
| CN (1) | CN1615135A (es) |
| AR (1) | AR037356A1 (es) |
| AT (1) | ATE383156T1 (es) |
| BR (1) | BR0214081A (es) |
| CA (1) | CA2466504A1 (es) |
| CO (1) | CO5580744A2 (es) |
| DE (1) | DE60224558T2 (es) |
| ES (1) | ES2297032T3 (es) |
| IL (1) | IL161991A0 (es) |
| MX (1) | MXPA04004476A (es) |
| NO (1) | NO20042440L (es) |
| PL (1) | PL369962A1 (es) |
| RU (1) | RU2004114552A (es) |
| TW (1) | TW200300680A (es) |
| WO (1) | WO2003041705A1 (es) |
| ZA (1) | ZA200403328B (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7785640B2 (en) * | 2004-01-16 | 2010-08-31 | Amerilab Technologies, Inc. | Effervescent composition including cranberry extract |
| DK1799196T3 (en) | 2004-10-08 | 2016-08-15 | Forward Pharma As | Controlled release pharmaceutical compositions comprising a fumaric acid ester |
| EP1928250A4 (en) * | 2005-09-27 | 2010-04-28 | Univ Kentucky Res Found | BERRY PREPARATIONS AND EXTRACTS |
| EP1940382A2 (en) * | 2005-10-07 | 2008-07-09 | Aditech Pharma AB | Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders |
| CA2661274A1 (en) * | 2006-08-29 | 2008-03-06 | University Of Kentucky Research Foundation | Compositions and methods for oral cancer chemoprevention using berry preparations and extracts |
| EP1902708A1 (de) * | 2006-09-25 | 2008-03-26 | Losan Pharma GmbH | Wirkstoff enthaltende stabilisierte feste Arzneimittelformen und Verfahren zu ihrer Herstellung |
| EP2433620A1 (en) * | 2007-10-12 | 2012-03-28 | AstraZeneca AB | Zibotentan Composition |
| CN109044985A (zh) | 2009-01-09 | 2018-12-21 | 前进制药知识产权有限公司 | 包含溶蚀骨架中的一种或多种富马酸酯的药物制剂 |
| JP6102120B2 (ja) * | 2012-08-16 | 2017-03-29 | ニプロ株式会社 | 医薬製剤およびその製造方法 |
| CN104771370B (zh) * | 2014-01-14 | 2020-07-24 | 南京圣和药业股份有限公司 | 帕瑞昔布钠冻干粉针剂及其制备方法 |
| CN104965041B (zh) * | 2015-06-11 | 2016-06-29 | 成都克莱蒙医药科技有限公司 | 一种帕瑞昔布钠异构体的高效液相色谱检测方法 |
| CN106074399B (zh) * | 2016-06-21 | 2018-11-02 | 马鞍山丰原制药有限公司 | 一种帕瑞昔布钠冻干制剂及其制备方法 |
| CN112409283A (zh) * | 2020-11-24 | 2021-02-26 | 苏州璞正医药有限公司 | 一种帕瑞昔布衍生物及其制备方法和应用 |
| WO2024208166A1 (zh) * | 2023-04-04 | 2024-10-10 | 上海汇伦医药股份有限公司 | 西维来司他用于镇痛的用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0729748B1 (en) * | 1993-11-18 | 2003-02-26 | Nippon Shinyaku Company, Limited | Process for producing stable medicinal composition |
| GB9523833D0 (en) * | 1995-11-22 | 1996-01-24 | Boots Co Plc | Medical treatment |
| SK285353B6 (sk) * | 1996-04-12 | 2006-11-03 | G. D. Searle & Co. | Substituované benzénsulfónamidy ako proliečivá COX-2 inhibítorov, farmaceutická kompozícia a spôsobich prípravy a použitia |
| SE9703693D0 (sv) * | 1997-10-10 | 1997-10-10 | Astra Pharma Prod | Novel combination |
| US6323226B1 (en) * | 1999-10-19 | 2001-11-27 | Texas Heart Institute | Treatment of heart disease with cox-2 inhibitors |
| BR0008059A (pt) * | 1999-12-08 | 2002-03-26 | Pharmacia Corp | Composições de valdecoxib |
| BR0016705A (pt) * | 1999-12-22 | 2002-09-24 | Pharmacia Corp | Composições de liberação dupla de um inibidor de ciclooxigenase-2 |
| PT1265860E (pt) * | 2000-03-24 | 2005-10-31 | Pharmacia Corp | Compostos amidino uteis como inibidores de sintase de oxido nitrico |
| AR035642A1 (es) * | 2000-05-26 | 2004-06-23 | Pharmacia Corp | Uso de una composicion de celecoxib para el alivio rapido del dolor |
| US6306842B1 (en) * | 2000-06-02 | 2001-10-23 | Medinox, Inc. | Protected forms of a combination of pharmacologically active agents and uses therefor |
| JP2004503588A (ja) * | 2000-07-13 | 2004-02-05 | ファルマシア・コーポレーション | 全身性疼痛および頭痛に対する選択的シクロオキシゲナーゼ−２阻害薬および血管調節化合物 |
| MY137736A (en) * | 2001-04-03 | 2009-03-31 | Pharmacia Corp | Reconstitutable parenteral composition |
-
2002
- 2002-11-12 KR KR1020047007335A patent/KR20050044459A/ko not_active Ceased
- 2002-11-12 ES ES02789593T patent/ES2297032T3/es not_active Expired - Lifetime
- 2002-11-12 RU RU2004114552/14A patent/RU2004114552A/ru not_active Application Discontinuation
- 2002-11-12 PL PL02369962A patent/PL369962A1/xx not_active Application Discontinuation
- 2002-11-12 AT AT02789593T patent/ATE383156T1/de not_active IP Right Cessation
- 2002-11-12 AR ARP020104341A patent/AR037356A1/es unknown
- 2002-11-12 CA CA002466504A patent/CA2466504A1/en not_active Abandoned
- 2002-11-12 EP EP02789593A patent/EP1446118B1/en not_active Expired - Lifetime
- 2002-11-12 MX MXPA04004476A patent/MXPA04004476A/es active IP Right Grant
- 2002-11-12 WO PCT/US2002/036253 patent/WO2003041705A1/en not_active Ceased
- 2002-11-12 IL IL16199102A patent/IL161991A0/xx unknown
- 2002-11-12 DE DE60224558T patent/DE60224558T2/de not_active Expired - Fee Related
- 2002-11-12 BR BR0214081-0A patent/BR0214081A/pt not_active IP Right Cessation
- 2002-11-12 JP JP2003543592A patent/JP2005509002A/ja active Pending
- 2002-11-12 US US10/292,682 patent/US20030100595A1/en not_active Abandoned
- 2002-11-12 CN CNA028270843A patent/CN1615135A/zh active Pending
- 2002-11-12 TW TW091133146A patent/TW200300680A/zh unknown
-
2004
- 2004-05-03 ZA ZA200403328A patent/ZA200403328B/en unknown
- 2004-05-07 CO CO04042439A patent/CO5580744A2/es not_active Application Discontinuation
- 2004-06-11 NO NO20042440A patent/NO20042440L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| KR20050044459A (ko) | 2005-05-12 |
| DE60224558T2 (de) | 2009-01-22 |
| EP1446118A1 (en) | 2004-08-18 |
| DE60224558D1 (de) | 2008-02-21 |
| EP1446118B1 (en) | 2008-01-09 |
| RU2004114552A (ru) | 2005-02-20 |
| ES2297032T3 (es) | 2008-05-01 |
| WO2003041705A1 (en) | 2003-05-22 |
| US20030100595A1 (en) | 2003-05-29 |
| MXPA04004476A (es) | 2004-08-11 |
| NO20042440L (no) | 2004-08-09 |
| CA2466504A1 (en) | 2003-05-22 |
| TW200300680A (en) | 2003-06-16 |
| AR037356A1 (es) | 2004-11-03 |
| JP2005509002A (ja) | 2005-04-07 |
| PL369962A1 (en) | 2005-05-02 |
| CN1615135A (zh) | 2005-05-11 |
| ZA200403328B (en) | 2005-04-13 |
| IL161991A0 (en) | 2005-11-20 |
| BR0214081A (pt) | 2004-09-28 |
| ATE383156T1 (de) | 2008-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5580744A2 (es) | Forma de dosificacion oral de un profarmaco de sulfonamida | |
| AR018732A1 (es) | Iminoazucares alquilados para prevenir, reducir o revertir la resistencia a la multidroga en el tratamiento quimioterapeutico y composicionfarmaceutica que los contiene. | |
| AR029216A1 (es) | Compuestos inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias; composicion farmaceutica y procedimiento de tratamiento | |
| PE20020307A1 (es) | Forma de dosificacion de farmaco activada por hidrogel | |
| KR950031069A (ko) | 골손실의 억제 및 혈청 콜레스테롤의 강하 방법 | |
| DK1313467T3 (da) | Hidtil ukendte farmaceutiske præparater til indgivelse af N-0923 | |
| MA27040A1 (fr) | Nucleosides substitues en 4' | |
| DK0715623T3 (da) | Blodpladeaggregationsinhibitorer | |
| SG147450A1 (en) | Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof | |
| HUP9902121A2 (hu) | Gonadotropin-leadó hormon antagonista hatású indolszármazékok és ezeket a vegyületeket tartalmazó gyógyszerkészítmények | |
| BR0008060A (pt) | Composições inibidoras de ciclooxigenase-2 tendo rápido inìcio de eficácia terapêutica | |
| NO962841D0 (no) | Anvendelse av 2-hydroksy-5-fenylazobenzosyrederivater som colon cancer kjemopreventativer og kjemoterapeutiske midler | |
| PE20050822A1 (es) | Derivados de florfenicol con mejor solubilidad en agua | |
| BR0014902A (pt) | Formulações orais para compostos antitumorais | |
| TR200101719T2 (tr) | Erkeklerde organik ereksiyona bağlı işlev bozukluğunun tedavisi için ilaç imalatında apomorfin kullanımı | |
| IL174665A0 (en) | Heterocyclic compounds which act as p-glycoprotein inhibitors and pharmaceutical compositions containing the same | |
| NO20026123D0 (no) | Farmasöytiske sammensetninger | |
| DE69315699D1 (de) | Inhibitoren gegen die aggregation von blutplättchen | |
| DK0804418T3 (da) | Platelataggregationshæmmere | |
| RU2007131435A (ru) | Противоопухолевое средство | |
| GT199800039A (es) | Atropisomeros de 3-heteroaril-4(3h)-quinazolinonas. | |
| ES2179526T3 (es) | Analogos y profarmacos del paclitaxel solubles en agua. | |
| CO5700738A2 (es) | Profarmaco de celecoxib | |
| ES2197781B1 (es) | Composiciones farmaceuticas liquidas de base acuosa en forma de suspension para la administracion por via oral de ibuprofeno. | |
| HRP20050872A2 (en) | Use of carbamazepine derivatives for the treatment of agitation in dementia patients |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Application withdrawn |